SEARCH

SEARCH BY CITATION

References

  • 1
    Di Bisceglie AM, Hoofhagle JH. Chronic viral hepatitis. In: ZakiniD, BoyerTD, eds. Hepatology: a textbook of liver disease. Ed 3. Philadelphia: Saunders, 1996: 12291329.
  • 2
    Tsai JF, Jeng JE, Chang WY, Lin ZY, Tsai JH. Hepatitis C virus infection among patients with chronic liver disease in an area hyperendemic for hepatitis B. Scand J Gastroenterol 1994; 29: 550552.
  • 3
    Tsai JF, Jeng JE, Chang WY, Ho MS, Lin ZY, Tsai JH. Independent and additive effect modification of hepatitis C and B viruses infection on the development of chronic hepatitis. J Hepatol 1996; 24: 271276.
  • 4
    Tsai JF, Jeng JE, Chang WY, Ho MS, Lin ZY, Tsai JH. Circulating immune complexes in chronic hepatitis C. J Med Virol 1995; 46: 1217.
  • 5
    Tsai JF, Jeng JE, Chang WY, Ho MS, Lin ZY, Tsai JH. Increased IgM-containing circulating immune complexes in patients co-infected with hepatitis C and hepatitis B. Medicine 1995; 74: 136143.
  • 6
    Tsai JF, Jeng JE, Chang WY, Ho MS, Lin ZY, Tsai JH. Circulating immune complexes in chronic hepatitis related to hepatitis C and B viruses infection. Clin Immunol Immunopathol 1995; 75: 3944.
  • 7
    Tsai JF, Chang WY, Jeng JE, Ho MS, Wang LY, Hsieh MY, Chern SC, et al. Hepatitis C virus infection as a risk factor for non-alcoholic liver cirrhosis in Taiwan. J Med Virol 1993; 41: 296300.
  • 8
    Tsai JF, Chang WY, Jeng JE, Ho MS, Lin ZY, Tsai JH. Hepatitis B and C virus infection as risk factors for liver cirrhosis and cirrhotic hepatocellular carcinoma: a case-control study. Liver 1994; 14: 98102.
  • 9
    Jeng JE, Tsai JF. Hepatitis C virus antibody in hepatocellular carcinoma in Taiwan. J Med Virol 1991; 34: 7477.
  • 10
    Tsai JF, Jeng JE, Ho MS, Chang WY, Lin ZY, Tsai JH. Hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Chinese: a case-control study. Int J Cancer 1994; 56: 619621.
  • 11
    Tsai JF, Chang WY, Jeng JE, Ho MS, Lin ZY, Tsai J. Effects of hepatitis C and B viruses infection on the development of hepatocellular carcinoma. J Med Virol 1994; 44: 9295.
  • 12
    Tsai JF, Chang WY, Jeng JE, Ho MS, Lin ZY, Tsai JH. Frequency of raised α-fetoprotein level among Chinese patients with hepatocellular carcinoma related to hepatitis B and C. Br J Cancer 1994; 69: 11571159.
  • 13
    Tsai JF, Margolis HS, Jeng JE, Ho MS, Ko YC, Lin ZY, Chang WY, et al. Association between hepatitis B and C virus infection and Chinese hepatocellular carcinoma: a case-control study. In: NishiokaK, SuzukiH, MishiroS, OdaT, eds. Viral hepatitis and liver disease. Tokyo: Springer -Verlag, 1994: 697700.
  • 14
    Tsai JF, Jeng JE, Ho MS, Chang WY, Hsiwh MY, Lin ZY, Tsai JH. Additive effect modification of hepatitis B surface antigen and e antigen on the development of hepatocellular carcinoma. Br J Cancer 1996; 73: 14981502.
  • 15
    Bissell DM, Maher JJ. Hepatic fibrosis and cirrhosis. In: ZakimD, BoyerTD, eds. Hepatology: a textbook of liver disease. Ed 3. Philadelphia: Saun-ders, 1996: 506525.
  • 16
    Border WA, Noble NA. Transforming growth factor β in tissue fibrosis. N Engl J Med 1994; 331: 12861292.
  • 17
    Malizia G, Brunt EM, Peters MG, Rizzo A, Broekelman TJ, McDonald JA. Growth factor and procollagen type I gene expression in human liver disease. Gastroenterology 1995; 108: 145156.
  • 18
    Friedman SL. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 1993; 328: 18281835.
  • 19
    Castilla A, Prieto J, Fausto N. Transforming growth factor β1 and α in chronic liver disease: effects of interferon alpha therapy. N Engl J Med 1991; 324: 933940.
  • 20
    Roberts AB, Sporn MB. The transforming growth factor betas. In: SpornMB, RobertsAB, eds. Peptide growth factors and their receptors. Heidelberg, Germany: Springer-Verlag, 1990: 419472.
  • 21
    Nakatsukassa H, Nagy P, Evarts RP, Hsia CC, Marsden E, Thorgeirsson SS. Cellular distribution of transforming growth factor-β1 and procollagen type I, III and IV transcripts in carbon tetrachloride-induced rat liver fibrosis. J Clin Invest 1990; 85: 18331843.
  • 22
    Nagy P, Schaf Z, Lapis K. Immunohistochemical detection of transforming growth factor-β in fibrotic liver disease. Hepatology 1991; 14: 269273.
  • 23
    Milani S, Herbst H, Schuppan D, Stein H, Surrenti C. Transforming growth factor β1 and TGFβ2 are differentially expressed in fibrotic liver disease. Am J Pathol 1991; 139: 12211229.
  • 24
    Bedossa P, Peltier E, Terris B, Franco D, Poynard. Transforming growth factor-beta1 (TGF-β1) and TGF-β1 receptors in normal, cirrhotic, and neo-plastic human livers. Hepatology 1995; 21: 760766.
  • 25
    Bedossa P, Paradis V. Transforming growth factor-1 (TGF-β): a key-role in liver fibrogenesis. J Hepatol 1995; 22 (suppl 2): 3742.
  • 26
    Roulot D, Durand H, Coste T, Rautureau J, Strosberg AD, Benarous R, Marullo S. Quantitative analysis of transforming growth factor β 1 messenger RNA in the liver of patients with chronic hepatitis C: absence of correlation between high levels and severity of disease. Hepatology 1995; 21: 298304.
  • 27
    Armendariz-Borunda J, Seyer JM, Kang AH, Raghow R. Regulation of TGF β gene expression in rat liver intoxicated with carbon tetrachloride. FASEB J 1990; 4: 215221.
  • 28
    Jakowlew SB, Mead JE, Danielpour D, Wu J, Roberts AB, Fausto N. Transforming growth factor β isoforms in rat liver regeneration: messenger RNA expression and activation of latent TGF-Beta. Cell Regul 1991; 2: 535548.
  • 29
    Jirtle RL, Carr BI, Scott CD. Modulation of insulin-like growth factor-II/ mannose 6-phosphate receptors and transforming growth factor-beta 1 during liver regeneration. J Biol Chem 1991; 266: 2244422450.
  • 30
    Gressner AM, Bachem MG. Molecular mechanisms of liver fibrogenesis- a homage to the role of activated fat-storing cells. Digestion 1995; 56: 335346.
  • 31
    Tsai JF, Jeng JE, Chuang LY, Yang MY, Ho MS, Chang WY, Hsieh MY, et al. Clinical evaluation of urinary transforming growth factor-β1 and serum α-fetoprotein as tumor markers of hepatocellular carcinoma. Br J Cancer 1997 (in press).
  • 32
    Tsai JF, Jeng JE, Chuang LY, Yang MY, Ho MS, Chang WY, Hsieh MY, et al. Urinary transforming growth factor-β1 in relation to serum α-fetoprotein in hepatocellular carcinoma. Scand J Gastroenterol 1997 (in press).
  • 33
    Chuang LY, Hon WC, Yang ML, Chang CC, Tsai JF. Urinary epidermal growth factor receptor-binding growth factors in the tumors of the digestive tract. Clin Biochem 1994; 27: 485489.
  • 34
    Chuang LY, Tsai JH, Yeh YH, Chang CC, Yeh HW, Guh JY, Tsai JF. Epidermal growth factor-related transforming growth factors in the urine of patients with hepatocellular carcinoma. Hepatology 1991; 13: 11121116.
  • 35
    Yeh YC, Tsai JF, Chuang LY, Yeh HW, Tsai JH, Florine DL, Tam JP. Elevation of transforming growth factor α and its relationship to the epidermal growth factor and β-fetoprotein levels in patients with hepatocellular carcinoma. Cancer Res 1987; 47: 896901.
  • 36
    Coupes BM, Newstead CG, Short CD, Brenchley PEC. Transforming growth factor β1 in renal allograft recipients. Transplantation 1994; 57: 17271731.
  • 37
    Sherwin SA, Twardzik DR, Bohn WH, Cockley KD, Todaro GJ. High-molecular-weight transforming growth factor activity in the urine of patients with disseminated cancer. Cancer Res 1983; 43: 403407.
  • 38
    Pugh RN, Murray-Lyon IM, Dawson JL, Peitroni MC, Williams R. Tran- section of the esophagus for bleeding esophageal varices. Br J Surg 1973; 60: 646649.
  • 39
    International Group. Acute and chronic hepatitis revisited. Lancet 1977; 2: 914919.
  • 40
    Roberts AB, Anzano MA, Meyers CA, Wideman J, Blacher R, Pan YCE, Stein S, et al. Purification and properties of a type beta transforming growth factor from bovine kidney. Biochemistry 1983; 22: 56925698.
  • 41
    Noh JW, Wiggins RC, Phan SH. Urinary transforming growth factor-beta activity is related to the degree of scarring in crescentic nephritis in the rabbit. Nephron 1993; 63: 7378.
  • 42
    Tsai JF, Margolis HS, Fields HA, Nainan OV, Chang WY, Tsai JH. Immu-noglobulin and hepatitis B surface antigen-specific circulating immune complexes in chronic hepatitis with hepatitis delta virus infection. J Med Virol 1990; 30: 2526.
  • 43
    Frei A, Zimmerman A, Weigand K The N-terminal propeptide of collagen type III in serum reflects activity and degree of fibrosis in patients with chronic liver disease. Hepatology 1984; 4: 830834.
  • 44
    Hanauske-Abel HM. Fibrosis: representative molecular elements, a basic concept, and emerging targets for suppressive treatment. In: ZakimD, BoyerTD, eds. Hepatology: a textbook of liver disease. Ed 3. Philadelphia: Saunders, 1996: 465506.
  • 45
    Castilla A, Prieto J. Human fibrogenesis and transforming growth factor beta-1. J Hepatol 1993; 18: 378379.
  • 46
    Suou T, Hosho K, Kishimoto Y, Horie Y, Kawasaki H. Long-term decrease in serum N-terminal propeptide of type III procollagen in patients with chronic hepatitis C treated with interferon alfa. Hepatology 1995; 22: 426431.
  • 47
    Anscher MS, Peters WP, Reisenbichler H, Petros WP, Jirtle RL. Transforming growth factor β as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med 1993; 328: 15921598.
  • 48
    Shirai Y, Kawata S, Tamura S, Ito N, Tsushima H, Takaishi K, Kiso S, et al. Plasma transforming growth factor-β1 in patients with hepatocellular carcinoma: comparison with chronic liver disease. Cancer 1994; 73: 22752279.
  • 49
    Annoni G, Weiner FR, Zern MA. Increased transforming growth factor-β1 gene expression in human liver disease. J Hepatol 1992; 14: 259264.
  • 50
    Chen DS. Natural history of chronic hepatitis B virus infection: new light on an old story. J Gastroenterol Hepatol 1993; 8: 470475.
  • 51
    Lin HH, Hsu HY, Chang MH, Hong KF, Young YC, Lee TY, Chen PJ, et al. Low prevalence of hepatitis C virus and infrequent perinatal or spouse infections in pregnant women in Taiwan. J Med Virol 1991; 35: 237240.
  • 52
    Tsai JF, Jeng JE, Ho MS, Wang CS, Chang WY, Hsieh MY, Lin ZY, et al. Serum alanine aminotransferase level in relation to hepatitis B and C viruses infection among blood donors. Liver 1997; 17: 2429.